Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Cancer Sci. 2019 Jul;110(7):2090-2099. doi: 10.1111/cas.14075. Epub 2019 Jun 10.
Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.
炎症在大多数癌症的发生和发展中起着至关重要的作用。趋化因子 C-C 基序趋化因子 2(CCL2)及其受体 C-C 趋化因子受体 2(CCR2)构成了炎症中的一个关键信号轴,最近基于其与癌症进展相关的证据,引起了广泛关注。Propagermanium(3-氧代锗丙酸聚合物)是一种有机锗化合物,在日本用于治疗乙型肝炎,可抑制 CCL2-CCR2 信号通路。本文综述了趋化因子 CCL2-CCR2 轴作为癌症治疗靶点的重要性,包括 Propagermanium 在内的药理学药物在小鼠和人类研究中的结果。